Indian Coronavirus Mutation Now Threatens Vaccine Development for COVID-19

---

---

A coronavirus strain isolated in India carried a mutation that could upend vaccine development around the globe, based on a new study from Australia and Taiwan. The strain in question was first sampled by the National Institute of Virology from a patient in Kerala.

The non-peer reviewed study said the change had occurred in the part of the spike protein that allows the virus to bind with certain human cells.

This structure targets cells containing ACE2, an angiotensin-converting enzyme 2– an enzyme attached to the outer surface of cells in the lungs, arteries, heart, kidney, and intestines, which also allowed the severe acute respiratory syndrome (Sars) virus to infect people.

As an approach to vaccine development, scientists have more knowledge about this receptor than any other, therefore most of them are working on antibodies that target it, but an unexpected structural change due to mutation could render them useless.

The researchers –- led by Wei-Lung Wang, from the National Changhua University of Education in Taiwan, and collaborators from Murdoch University in Australia – stated this was the first report of a significant mutation that could threaten the development of a vaccine for the virus that causes COVID-19.

Current vaccine development against Sars-CoV-2 is at great risk of becoming futile

We know that with flu viruses. The speed at which the flu virus evolves and the fact that numerous strains can be active in any given flu season, engineering an effective vaccine is daunting.

In a paper released on the preprint review website on Saturday the researcher say.“The observation of this study raised the alarm that Sars-CoV-2 mutation with varied epitope (something an antibody attaches itself to) profile could arise at any time.”

“It means current vaccine development against Sars-CoV-2 is at great risk of becoming futile.”

Moreover, the strain in question was first sampled by the National Institute of Virology from a patient in Kerala as early as January, the full genome sequence was only released to the international community last month – the delay also raised eyebrows among some researchers.

The patient was among the first three cases diagnosed in India, a medical student returning from Wuhan, but the strain does not appear to be closely related to any of those identified in the Chinese city and appears to be a different variant from the recorded in other countries.

The researchers found that the mutation occurred in the spike protein’s receptor-binding domain (RBD). A computer simulation shows that the RBD mutation, which was not found in other variants across the globe, could remove a hydrogen bond from the spike protein.

In absence of this bond, the virus may be less likely to bind with ACE2, or angiotensin-converting enzyme-2, which is found in the lungs and other organs.

Since its first confirmed identification in early January, the virus has reached every continent except for Antarctica with more than 3,500 mutations detected, according to the China National Centre for Bioinformation.

For a long time, India appeared to have been spared by the COVID-19 pandemic, but it has now recorded more than 10,000 confirmed cases.

For Coronavirus India number update, follow the link.

The virus’s spread in the country has grown rapidly in recent weeks, with cases being identified in crowded slum areas like Dharavi, and scientists fear the world’s second-biggest country could see the next major outbreak -– something that threatens a humanitarian disaster. India has already extended its 21 days lockdown to a further 19 days till 3rd May.

Even with so much information, the international community still knows relatively less about the evolution and spread of the virus as many aspects of research are ongoing across the world and in India.

A researcher with the Chinese Academy of Sciences in Beijing who is tracking the mutation of the coronavirus said he was closely monitoring the emerging strains from India.

Some vaccines have already started clinical trials in China and the US, but the RDB mutation could possibly add a new dimension of uncertainty about the eventual outcome.

It must be noted that the findings of the new study, which was not peer-reviewed, will need further verification. For instance, there was a possibility that the mutation was caused by a technical error during the sequencing process, according to the researcher, who requested not to be named due to the sensitivity of the issue, as reported by the South China Morning Post.

He also said the results produced by the computer simulation may be misleading.“Laboratory experiments will be needed to verify whether the protein changes in real life,” said the researcher.

Benjamin Neuman, professor and chair of biological sciences with the Texas A&M University in Texarkana, said the mutation appeared to be random, not the result of natural selection by the immune system because there were no more variants in that part of the spike than elsewhere in the genome.

He also agreed that the computer modeling might need improvement. “The mutation could make a small difference in binding affinity, though the actual effect of this mutation would be difficult to predict and would be better tested experimentally,” Neuman said.

The constant mutation of the coronavirus means the vaccine will need periodic tests and updates. “The influenza virus mutates constantly, and at about the same rate as coronavirus, but we are able to successfully vaccinate against this moving target,” he said. “Finding a vaccine strategy that actually works in people is the difficult part.”

The unusual behavior of the coronavirus has kept scientists around the world scratching their heads. For instance, it has infected a large number of patients around the world but the genetic structure of the strain has remained relatively stable.

Some researchers have speculated that it might have been spreading quietly in humans for a long time and evolved into a form that did not require too many changes to adapt to different environments and populations.

But others worry the thousands of strains sampled and sequenced are just the tip of the iceberg – and greater variety increases the risk that new strains will require new vaccines in the same way the flu virus does.

Although China has five different vaccines under development “it is impossible to predict which one is more likely to succeed”, said the researcher. “They could all end in failure.”